– Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress. This lead-in represents the first ever 90mg dosing of eftilagimod alpha (“efti”), a soluble LAG-3 protein and MHC Class II agonist, given in combination with weekly paclitaxel.
Earlier: Immutep Data From Safety Lead-in Phase of AIPAC-003 Confirmed Complete Response In A Patient With Metastatic Breast Cancer Refractory To Several Lines Of Therapy Achieved During Combination Treatment With 90mg Efti And Paclitaxel
Company Profile
Wed. 15 May 2024, 5:17am ET
Benzinga
News, Events